Submit a Manuscript to the Journal

International Journal of Nanomedicine

For an Article Collection on

Nanomedicine for Cancer Immunotherapy

Manuscript deadline
29 February 2024

Cover image - International Journal of Nanomedicine

Article collection guest advisor(s)

Prof. Dr. Guangya Xiang, Huazhong University of Science and Technology
[email protected]

Prof. Dr. Songwei Tan, Huazhong University of Science and Technology
[email protected]

Submit an ArticleVisit JournalArticles

Nanomedicine for Cancer Immunotherapy

Cancer Immunotherapy is a therapy used to treat cancer patients that involves or uses components of the immune system, including antibodies (e.g. anti-PD1/PD-L1), vaccines and T cell infusions, which is a revolutionary technology in oncology. Cancer immunotherapy has made great progress in the past decades and it is thought to be an effective strategy for achieving long-term success in cancer treatment. Despite some clinical successes, some issues, including low patient response rates, adverse effects/immune-related toxicities, and acquired immune resistance need to be solved. The development of new nanoparticles, including lipid nanoparticles, nano-sized metal-organic frameworks, polymeric nanoparticles/micelles/nanogels, inorganic nanoparticles and cell membrane derived systems, have offered effective solutions for targeting delivery of the cargoes, boosting antitumor immune responses, sensitizing tumors to immunotherapy, and/or reducing adverse effects. Nanomedicines can also remodel the tumor immune-microenvironment, induce immunogenic cell death(ICD) of cancer cells to improve cancer immunotherapy and even realize sequential release of different drugs to induce cascade immune response. Furthermore, the combination of nanotechnology and immunotherapy offers new perspectives on strengthening antitumor immune responses. For example, clinical trials have proven the advantages of the treatment strategy of albumin paclitaxel nanoparticle-PD-L1 monoclonal antibody combination therapy.

This Article Collection aims to show recent progress in cancer immunotherapy by using nanotechnology. We hope this Collection can help researchers to deepen the mechanisms by which tumor cells evade immunity, reveal how nanomedicine can strengthen the anti-tumor immune-response, and discuss how nanomedicine overcomes the challenges and the critical limitations of cancer immunotherapy. We also hope to offer a platform to inspire future directions in this field.

Potential subtopics related to recurrent miscarriage include (but are not limited to):
• Nano-vaccines for antigens, peptides or mRNA delivery
• Nanomedicine for cell therapy
• Nanomedicine for reprogram of tumor immune-microenvironment
• Targeting delivery of cancer immunotherapy drugs
• Novel nanoparticles for cancer immunotherapy
• Exosomes/ cell derived vesicles for cancer immunotherapy
• Combination of nanomedicine and cancer immunotherapy
• Interaction between nanoparticles and the immune system

All manuscripts submitted to this Article Collection will undergo full peer-review; Guest Advisors will not be handling submitted articles. Please review the journal’s aims and scope and author submission instructions prior to submission.

Please submit your manuscript through the Dovepress website. During submission, enter the promo code FXKES to indicate that your article should be considered for this Collection.

The manuscript submission deadline is 29 February 2024.

Please contact Haoyang Yi at [email protected] with any queries regarding this Article Collection.

Guest advisors

Dr. Guangya Xiang received his Ph.D. from Tongji Medical College in 2000. His research interests include nanoscale drug delivery system, drug synthetic technology and medical imaging nanotechnology. He has published more than 100 articles such as Journal of Controlled Release, Acta Pharmaceutica Sinica B, Acta biomaterialia, Angewandte Chemie International Edition, Chemical Engineering Journal, Bioactive Materials, Theranostics, with the H-index of 30.

Dr. Songwei Tan received his Ph.D. from Zhejiang University in 2011. His research interests include polymeric drug delivery system and gene therapy. He has published more than 70 articles such as Journal of Controlled Release, Acta Pharmaceutica Sinica B, Ebiomedicine, Acta biomaterialia, Nano Research, Nanoscale Horizons, with the H-index of 27.

Benefits of publishing open access within Taylor & Francis

Global marketing and publicity, ensuring your research reaches the people you want it to.

Article Collections bring together the latest research on hot topics from influential researchers across the globe.

Rigorous peer review for every open access article.

Rapid online publication allowing you to share your work quickly.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.